公开(公告)号：EP2004163B1

公开(公告)日：2014-09-17

申请号：EP07781370.7

申请日：2007-04-05

申请人： Novartis Pharma AG ,  Novartis Pharma GmbH

发明人： BURKE, Gregory ,  LANE, Heidi ,  LINNARTZ, Ronald Richard ,  VERSACE, Richard William

IPC分类号： A61K31/132 ,  A61K31/136 ,  A61K31/282 ,  A61K31/436 ,  A61K31/437 ,  A61K31/475 ,  A61K31/5375 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/675 ,  A61K31/132 ,  A61K31/136 ,  A61K31/282 ,  A61K31/436 ,  A61K31/437 ,  A61K31/475 ,  A61K31/5375 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP2675451A1

公开(公告)日：2013-12-25

申请号：EP12705608.3

申请日：2012-02-17

申请人： Novartis Pharma AG ,  Incyte Corporation

发明人： VANNUCCHI, Alessandro, M. ,  BOGANI, Costanza ,  GUGLIELMELLI, Paola

IPC分类号： A61K31/436 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/519 ,  A61K31/436 ,  A61K45/06 ,  A61K2300/00

摘要： Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including MPNs. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.

公开(公告)号：EP2165703A2

公开(公告)日：2010-03-24

申请号：EP09157626.4

申请日：2005-01-17

申请人： Novartis Pharma AG ,  Novartis Pharma GmbH

发明人： Kowalski, James ,  Lakshman, Jay Parthiban ,  Patel, Arun P.

IPC分类号： A61K9/20

CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K31/40 ,  C07D207/16 ,  Y10T428/268

摘要： Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile.

摘要翻译： 可以为98.5-100％纯度的二肽基肽酶IV抑制剂（本文称为DPP-IV）是能够用特定赋形剂直接压制成销售形式剂型的高剂量药物，例如具有所需硬度， 分解能力和可接受的溶解特性。 DPP-IV不是固有的可压缩性，因此提出了制剂问题。 制剂中使用的赋形剂增强了药物和压片混合物的流动和压实性能。 最佳流量有助于均匀的模头填充和重量控制。 使用的粘结剂确保足够的内聚性能，使DPP-IV能够使用直接压缩方法进行压缩。 所生产的片剂提供可接受的体外溶出曲线。

公开(公告)号：EP2072049A3

公开(公告)日：2009-12-30

申请号：EP09004205.2

申请日：2001-06-20

申请人： Novartis AG ,  Novartis Pharma AG

发明人： Ganter, Sabina Maria ,  Wagner, Robert Frank

IPC分类号： A61K31/41 ,  A61K9/20

CPC分类号： A61K9/2054 ,  A61K9/2027

摘要： The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.

公开(公告)号：EP2132216A1

公开(公告)日：2009-12-16

申请号：EP08708805.0

申请日：2008-02-07

申请人： Novartis Pharma AG

发明人： YIN, Zheng ,  DURAISWAMY, Jeyaraj ,  CHEN, Yen, Liang

IPC分类号： C07H19/23 ,  A61K31/7064 ,  A61P31/12

CPC分类号： C07H19/23

摘要： This invention relates to novel nucleoside compounds of formula (I) that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.

公开(公告)号：EP1810715A3

公开(公告)日：2009-12-16

申请号：EP07108093.1

申请日：2001-11-20

申请人： Novartis AG ,  Novartis Pharma AG

发明人： Wood, Jeanette Marjorie ,  Brandt, Ralf ,  Bold, Guido ,  Traxler, Peter

IPC分类号： A61P35/00 ,  A61K45/06 ,  A61K31/505 ,  A61K31/70

CPC分类号： A61K45/06 ,  A61K31/505 ,  A61K31/70 ,  A61K31/50 ,  A61K31/335 ,  A61K2300/00

摘要： The invention relates to a combination which comprises a first active ingredient which is a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF), in particular, for the delay of progression or treatment of a disease associated with deregulated angiogenesis, especially a proliferative disease; a pharmaceutical composition comprising such a combination; a commercial package comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal, especially a human.

公开(公告)号：EP2004221A2

公开(公告)日：2008-12-24

申请号：EP07773740.1

申请日：2007-03-22

申请人： Novartis Pharma AG

发明人： JANATPOUR, Mary, J. ,  YU, Guoying, K.

IPC分类号： A61K39/00 ,  A61K47/48 ,  C07K16/30

CPC分类号： C07K16/30 ,  A61K47/6851 ,  A61K51/1045 ,  A61K2039/505 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57492

摘要： Methods of diagnosing, detecting or treating cancer where the cancer expresses a tumor cell antigen that is elevated relative to the normal adjacent tissue, by administering an antibody or antibody fragment which binds to that tumor cell antigen. The methods involve the use of antibodies that bind to the tumor cell antigens KIAA1815, LOC157378, FU20421, DSCD75, GPR160, GPCR41, and SLC1A5.

公开(公告)号：EP1973782A1

公开(公告)日：2008-10-01

申请号：EP07712035.0

申请日：2007-01-15

申请人： Novartis Pharma AG ,  NOVARTIS-PHARMA GMBH

发明人： BIEL, Roger ,  GRUHN, Torsten

IPC分类号： B65B25/00 ,  B65B57/10 ,  G01N21/88

CPC分类号： B65B25/008 ,  B65B57/10 ,  G01N21/9508

摘要： The invention relates to a method and apparatus for detecting the presence of an ophthalmic lens, particularly a contact lens (5), in a package (2). The method for detecting the presence of an ophthalmic lens, particularly a contact lens, in a package, is characteilsed in that the package is checked for presence of an ophthalmic lens with a x-ray detection system (6) and with an optical detection system (9), whereby presence of an ophthalmic lens is given if either one or both cameras detect presence of an ophthalmic lens.

公开(公告)号：EP1938074A1

公开(公告)日：2008-07-02

申请号：EP06806192.8

申请日：2006-10-11

申请人： Novartis Pharma AG ,  NOVARTIS-PHARMA GMBH

发明人： BIEL, Roger ,  LÄSSIG, Günter ,  HAGMANN, Peter

IPC分类号： G01M11/02

CPC分类号： G01M11/0207

摘要： The invention relates to a cuvette for an ophthalmic lens, for testing the latter using an optical inspection system, said cuvette comprising a hollow space (11) to be filled with a liquid and has an axis (12) coinciding, in the test position of the cuvette, with the optical axis of an inspection system and, between a first viewing glass (13) at the top and a second viewing glass (15) at the bottom, a removable lens support (16) is arranged in the lower area of the hollow space (11), so as to allow a free floating inspection of the lens (14) at a defined inspection position when the lens support (16) is removed.

公开(公告)号：EP1924551A2

公开(公告)日：2008-05-28

申请号：EP06791701.3

申请日：2006-08-29

申请人： Novartis Pharma AG

发明人： FLOR, Peter, Josef ,  MARZINZIK, Andreas ,  NOZULAK, Joachim ,  OFNER, Silvio ,  ROY, Bernard ,  SPANKA, Carsten

IPC分类号： C07C237/04 ,  C07C237/06 ,  C07D215/08 ,  C07D217/06 ,  C07D217/04 ,  C07D265/38 ,  C07D209/86 ,  C07D233/22 ,  C07D311/68 ,  C07D209/40 ,  C07D451/14 ,  C07D209/42 ,  C07D307/68 ,  C07D263/58 ,  C07D401/04

CPC分类号： C07D209/42 ,  C07C211/29 ,  C07C217/58 ,  C07C237/04 ,  C07C237/06 ,  C07C237/22 ,  C07C2601/02 ,  C07C2602/10 ,  C07C2603/20 ,  C07D209/16 ,  C07D209/86 ,  C07D211/58 ,  C07D213/38 ,  C07D213/85 ,  C07D215/08 ,  C07D217/04 ,  C07D217/06 ,  C07D223/26 ,  C07D223/28 ,  C07D263/58 ,  C07D265/38 ,  C07D307/79 ,  C07D311/68 ,  C07D401/06 ,  C07D401/14 ,  C07D405/12 ,  C07D495/04

摘要： The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

摘要翻译： 本发明涉及新的式（I）二胺，其中所有变量如说明书中所定义，游离碱形式或酸加成盐形式，它们的制备，它们作为药物的用途和包含它们的药物。